United Therapeutics revenue and financials

UTHR · NASDAQ · USD

Compare United Therapeutics
$554.73Change from previous close: −0.78%Absolute change: −$4.37

Close · November 20, 2026

In the fiscal year ended December 2025, United Therapeutics reported revenue of $3.18B (+10.61% year over year). Net income was $1.33B, a net margin of 41.9%.

Annual revenue · 2025: $3.18B
  1. $1.6B2016
  2. $1.73B2017
  3. $1.63B2018
  4. $1.45B2019
  5. $1.48B2020
  6. $1.69B2021
  7. $1.94B2022
  8. $2.33B2023
  9. $2.88B2024
  10. $3.18B2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+10.61%
2025 vs 2024
Net income growth
+11.68%
2025 vs 2024
Net margin
41.9%
2024: 41.5%

How United Therapeutics is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue3,1832,8772,3281,9361,6861,4831,4491,6281,7251,599
Cost of revenue38431025815212310811819910672.7
Gross profit2,7982,5682,0701,7851,5631,3751,3311,4291,6201,526
Selling, general and administrative731635474473466421335269333319
Research and development5504814083235403581,183358265148
Operating income1,4931,3771,185980556594-1888058151,062
EBIT1,5171,4521,188989687596-1788031,0221,059
EBITDA1,6031,5241,2421,040737646-1328381,0531,091
Interest expense19.542.959.332.418.623.544.213.99.03.9
Pre-tax income1,7141,5391,274951594639-1657597701,060
Income tax379344290223118124-60.5170352347
Net income1,3351,195985727476515-105589418714
Net income to common shareholders1,3351,195985727476515-105589418714
Basic EPS30.1326.4421.0415.9810.6011.65-2.3913.549.5016.29
Diluted EPS27.8624.6419.8115.0010.0611.54-2.3913.399.3115.25
Average shares (basic)44.345.246.845.544.944.243.843.544.043.8
Average shares (diluted)47.948.549.748.547.344.643.844.044.946.8

Companies in the group: same industry, similar size